0RAE Stock Chart & Stats
€0.69
€0.00(0.00%)
At close: 4:00 PM EDT
€0.69
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€0.63 - €1.19
Previous CloseN/A
Volume4.00
Average Volume (3M)5.62K
Market Cap
€55.69M
Enterprise Value€67.72M
Total Cash (Recent Filing)€4.72M
Total Debt (Recent Filing)€12.24M
Price to Earnings (P/E)―
Beta1.06
Next Earnings
Sep 24, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.12
Shares Outstanding77,817,220
10 Day Avg. Volume4,168
30 Day Avg. Volume5,618
Financial Highlights & Ratios
PEG Ratio1.15
Price to Book (P/B)-13.62
Price to Sales (P/S)0.00
P/FCF Ratio-9.84
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.14
Revenue Forecast (FY)€4.05M
Bulls Say, Bears Say
Bulls Say
Proprietary Biological PlatformAmoéba’s Willaertia magna platform is a differentiated biological technology with application across biocontrol and biofertilizers. A proprietary organism-based platform can create durable product pipelines, regulatory barriers to entry, and cross-product leverage as markets shift toward biologicals.
Multiple Commercial PathwaysThe business model supports direct product sales, licensing/partnership income and R&D/service revenues. This structural diversity can reduce single-market dependency, enable upfront and milestone cash from partners, and allow scale via royalties as approvals and partnerships mature.
Lean Team And Partner-driven ManufacturingA small headcount and stated use of industrialization partners imply an asset-light model. That reduces fixed costs and enables flexible capacity scaling through partners, which supports lower incremental capital needs and faster commercialization if product registrations and distribution deals succeed.
Bears Say
Collapsed Revenue And Persistent LossesReported revenue collapsing to zero in 2025 and ongoing large operating losses show weak commercial traction. Without predictable product sales, the firm cannot self-fund registrations or build distribution, making sustained margin improvement unlikely absent material market wins.
Negative Equity And Rising LeverageNegative equity across multiple years and a material rise in debt dramatically increase refinancing and solvency risk. This constrains strategic options, raises cost of capital, and can force dilutive financing or restrictive covenants that impede long-term investment in registrations and commercialization.
Consistent Cash BurnPersistent negative operating and free cash flow indicate ongoing external funding needs. Even with partial improvement, sustained cash burn undermines runway for product development and market roll-out, heightening execution risk until durable revenue streams materialize.
Amoeba SA News
0RAE FAQ
What was Amoeba SA’s price range in the past 12 months?
Amoeba SA lowest share price was €0.63 and its highest was €1.19 in the past 12 months.
What is Amoeba SA’s market cap?
Amoeba SA’s market cap is €55.69M.
When is Amoeba SA’s upcoming earnings report date?
Amoeba SA’s upcoming earnings report date is Sep 24, 2026 which is in 50 days.
How were Amoeba SA’s earnings last quarter?
Amoeba SA released its earnings results on Mar 26, 2026. The company reported -€0.066 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.066.
Is Amoeba SA overvalued?
According to Wall Street analysts Amoeba SA’s price is currently Overvalued.
Does Amoeba SA pay dividends?
Amoeba SA does not currently pay dividends.
What is Amoeba SA’s EPS estimate?
Amoeba SA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Amoeba SA have?
Amoeba SA has 77,817,220 shares outstanding.
What happened to Amoeba SA’s price movement after its last earnings report?
Amoeba SA reported an EPS of -€0.066 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -8.588%.
Which hedge fund is a major shareholder of Amoeba SA?
Currently, no hedge funds are holding shares in GB:0RAE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Amoeba SA
Amoéba S.A. focuses on the development and commercialization of anti-microbial and anti-fungal products. The company's primary innovation centers on harnessing the unique properties of the Willaertia magna C2c Maky amoeba, which it is applying across various fields. These applications are designed to mitigate biological risks in critical areas like water purification, the treatment of human injuries, and safeguarding agricultural crops. Established in 2010, Amoéba S.A. is based in Chassieu, France.